Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

被引：0
|
作者：
Michele Kohli
Donna Lawrence
Jennifer Haig
Andrea Anonychuk
Nadia Demarteau
机构：
[1] OptumInsight,
[2] Health Economics and Outcomes Research,undefined
[3] GlaxoSmithKline Biologicals,undefined
[4] Global Vaccines Development,undefined
来源：
BMC Public Health | / 12卷
关键词：
Human papillomavirus; Cervical cancer; Vaccine; Cost-effectiveness; Markov model; Canada;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women
    Munoz, Nubia
    Kjaer, Susanne K.
    Sigurdsson, Kristjan
    Iversen, Ole-Erik
    Hernandez-Avila, Mauricio
    Wheeler, Cosette M.
    Perez, Gonzalo
    Brown, Darron R.
    Koutsky, Laura A.
    Tay, Eng Hseon
    Garcia, Patricia J.
    Ault, Kevin A.
    Garland, Suzanne M.
    Leodolter, Sepp
    Olsson, Sven-Eric
    Tang, Grace W. K.
    Ferris, Daron G.
    Paavonen, Jorma
    Steben, Marc
    Bosch, F. Xavier
    Dillner, Joakim
    Huh, Warner K.
    Joura, Elmar A.
    Kurman, Robert J.
    Majewski, Slawomir
    Myers, Evan R.
    Villa, Luisa L.
    Taddeo, Frank J.
    Roberts, Christine
    Tadesse, Amha
    Bryan, Janine T.
    Lupinacci, Lisa C.
    Giacoletti, Katherine E. D.
    Sings, Heather L.
    James, Margaret K.
    Hesley, Teresa M.
    Barr, Eliav
    Haupt, Richard M.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (05): : 325 - 339
  • [22] Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine
    Chen, Jing
    Gopala, Kusuma
    Akarsh, P. K.
    Struyf, Frank
    Rosillon, Dominique
    OPEN FORUM INFECTIOUS DISEASES, 2019, 6 (12):
  • [23] Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04 Adjuvanted Vaccine in Healthy Males Aged 10-18 Years
    Lehtinen, M.
    Petaja, T.
    Keranen, H.
    Karppa, T.
    Kawa, A.
    Lantela, S.
    Levanen, H.
    Tocklin, T.
    Godeaux, O.
    Dubin, G.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 : E174 - E174
  • [24] Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
    Einstein, Mark H.
    Takacs, Peter
    Chatterjee, Archana
    Sperling, Rhoda S.
    Chakhtoura, Nahida
    Blatter, Mark M.
    Lalezari, Jacob
    David, Marie-Pierre
    Lin, Lan
    Struyf, Frank
    Dubin, Gary
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (12) : 3435 - 3445
  • [25] Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years
    Romanowski, B.
    de Borba, P. Colares
    Naud, P. S.
    Roteli-Martins, C. M.
    De Carvalho, N. S.
    Teixeira, J. C.
    Aoki, F.
    Ramjattan, B.
    Shier, R. M.
    Somani, R.
    Barbier, S.
    Blatter, M. M.
    Chambers, C.
    Ferris, D.
    Gall, S. A.
    Guerra, F. A.
    Harper, D. M.
    Hedrick, J. A.
    Henry, D. C.
    Korn, A. P.
    Kroll, R.
    Moscicki, A-B
    Rosenfeld, W. D.
    Sullivan, B. J.
    Thoming, C. S.
    Tyring, S. K.
    Wheeler, C. M.
    Dubin, G.
    Schuind, A.
    Zahaf, T.
    LANCET, 2009, 374 (9706): : 1975 - 1985
  • [26] Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women
    Bhatla, Neerja
    Suri, Vanita
    Basu, Partha
    Shastri, Surendra
    Datta, Sanjoy K.
    Bi, Dan
    Descamps, Dominique J.
    Bock, Hans L.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2010, 36 (01) : 123 - 132
  • [27] Efficacy of Human Papillomavirus Type 16/18 AS04-Adjuvanted Vaccine in Japanese Women Aged 20 to 25 Years
    Konno, Ryo
    Tamura, Shinobu
    Dobbelaere, Kurt
    Yoshikawa, Hiroyuki
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (05) : 847 - 855
  • [28] Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: Follow-up through Month 48 in a Phase III randomized study
    Einstein, Mark H.
    Levin, Myron J.
    Chatterjee, Archana
    Chakhtoura, Nahida
    Takacs, Peter
    Catteau, Gregory
    Dessy, Francis J.
    Moris, Philippe
    Lin, Lan
    Struyf, Frank
    Dubin, Gary
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (12) : 3455 - 3465
  • [29] Re: Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women
    Brewer, Noel T.
    Reiter, Paul L.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (19) : 1517 - 1517
  • [30] Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine For the Prevention of Genital Warts in Males
    Garnock-Jones, Karly P.
    Giuliano, Anna R.
    DRUGS, 2011, 71 (05) : 591 - 602
12345